Search results
'An Officer and a Gentleman' actor Louis Gossett Jr. died from COPD, report says: What to know about...
Yahoo Canada Style· 4 days agoThis article is for informational purposes only and is not a substitute for professional medical...
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 7 days agoKey opinion leaders (KOLs) interviewed by GlobalData have expressed mixed opinions about Fasenra,...
Earnings call: Regeneron reports steady growth, prepares for new launches By Investing.com
Investing.com· 3 days agoThis growth was primarily driven by strong sales of Dupixent and Libtayo, as well as collaboration...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Morningstar· 5 days agoSociety (ATS) 2024 International Conference taking place May 12-22 in San Diego. "We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with ...
Earnings call: Pulmonx sees 30% sales boost in Q1, eyes $84M annual target By Investing.com
Investing.com· 4 days agoPulmonx Corporation (ticker: LUNG) reported a robust start to 2024 with a 30% increase in worldwide...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 3 days agoRegeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi's sBLA for Dupixent for COPD treatment was accepted by the FDA for priority review, highlighting ...
What’s Going Around: Seasonal allergies, strep throat, influenza, stomach viruses, COVID
ClickOnDetroit· 3 days agoHere’s our weekly round-up of what illnesses are spreading the most in Metro Detroit communities,...
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 4 days agoRegeneron stock is forming a flat base with a buy point at 998.33, according to MarketSurge. That's...
Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020
WPRI Providence· 6 days agoForesee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia. The Phase 1 clinical trial is a ...